Clinical Trials
22 trialsNCT06900595 2026-05-22
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07281417 2026-05-22
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07603856 2026-05-22
REVIVE
University of Chicago
Phase 2 Not yet recruiting
NCT06448026 2026-05-20
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06787612 2026-05-20
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT06855212 2026-05-20
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06860815 2026-05-20
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT07195734 2026-05-19
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05574101 2026-05-15
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07058012 2026-05-15
EMPIRE
NSABP Foundation Inc
Phase 2 Recruiting
NCT05208944 2026-05-13
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Active not recruiting
NCT06980038 2026-05-13
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05669989 2026-05-11
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT05694871 2026-05-11
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05557591 2026-05-06
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT06205836 2026-05-06
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06651593 2026-05-06
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06769698 2026-05-06
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT07224022 2026-05-06
NACho
Duke University
Phase 2 Not yet recruiting
NCT07281768 2026-05-06
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT05961709 2026-05-04
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting